|
 |
Our pioneering product portfolio includes ABLAVAR®(gadofosveset trisodium)—the first and only FDA approved blood pool contrast agent for magnetic resonance angiography (MRA), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), the world’s leading cardiac perfusion imaging agent and DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, the leading cardiac ultrasound contrast agent in the US.
For comprehensive information about our products, including full Prescribing Information, and support services, please select a product below:
 ABLAVAR ® (gadofosveset trisodium)
_RGB.jpg)
Ordering Information:
To place an order call
1-800-299-3431
|
Product Information:
Product Website
Material Safety Data Sheet (MSDS) (PDF)
Full Prescribing Information including boxed WARNING regarding Nephrogenic Systemic Fibrosis (NSF) (PDF)
INDICATIONS: ABLAVAR® is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
CONTRAINDICATIONS: History of a prior allergic reaction to a gadolinium-based contrast agent.
IMPORTANT SAFETY INFORMATION:
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.
- The risk for NSF appears highest among patients with:
- chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), or
- acute kidney injury.
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
- For patients at highest risk for NSF, do not exceed the recommended ABLAVAR dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration.
|
ABLAVAR® Injection: As with other contrast media, the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered. As with other gadolinium based contrast agents, caution should be exercised in patients with renal insufficiency due to the possibility of further deterioration in renal function.
In clinical trials, a small increase (2.8 msec) in the average change from baseline in QTc was observed at 45 minutes following ABLAVAR® administration. These QTc prolongations were not associated with arrhythmias or symptoms. Caution should be used in patients at high risk for arrhythmias due to baseline QTc prolongation.
Have emergency resuscitative equipment available prior to and during ABLAVAR® administration.
Please See Full Prescribing Information including boxed WARNING regarding Nephrogenic Systemic Fibrosis (NSF)
ABLAVAR® List Price History
|
|
DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Ordering Information:
| Catalog Numbers |
| DE4 |
4-Vial Kit US |
| VMIX |
VIALMIX® |
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com
|
Product Information:
Product Website
Material Safety Data Sheet (MSDS) (PDF)
Full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.
DEFINITY® Return Policy
INDICATIONS
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
CONTRAINDICATIONS
Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.
IMPORTANT SAFETY INFORMATION
WARNING: Serious Cardiopulmonary Reactions
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [See WARNINGS AND PRECAUTIONS (5.1)]. Most serious reactions occur within 30 minutes of administration.
|
In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration [See ADVERSE REACTIONS (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions [See Postmarketing Experience (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.
Please see full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.
DEFINITY® List Price History
|
|
Cardiolite ® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection)
Ordering Information:
| Catalog Numbers |
| CAPD |
20-Vial Kit |
| CAKD |
5-Vial Kit |
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com |
Product Information:
Product Website
Material Safety Data Sheet (MSDS) (PDF)
Prescribing Information (PDF)
Important Safety Information:
Exercise and pharmacologic stress testing should be performed only under the supervision of a qualified physician. Cardiolite® has been rarely associated with acute severe allergic and anaphylactic events of angioedema and generalized urticaria. The most frequently reported adverse events include headache, chest pain/angina, ST segment changes on ECG, nausea, and abnormal taste and smell. |
|
VIALMIX ®
Ordering Information:
| Catalog Numbers |
| VMIX |
VIALMIX®* |
| *A VIALMIX® is provided at no charge to customers who use DEFINITY® |
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com |
Product Information:
VIALMIX® is the activation device used with DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
When properly used, it ensures consistent activation of DEFINITY® each and every time.
INDICATIONS
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
CONTRAINDICATIONS
Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.
IMPORTANT SAFETY INFORMATION
WARNING: Serious Cardiopulmonary Reactions
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [See WARNINGS AND PRECAUTIONS (5.1)]. Most serious reactions occur within 30 minutes of administration.
|
In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration [See ADVERSE REACTIONS (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions [See Postmarketing Experience (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.
Please see full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.
|
|
INTELLIPIN ® (Dispensing Pin)
|
Ordering Information:
| Catalog Numbers |
| IPIN |
Box of 4 Intellipins® |
To place an order call
1-800-299-3431
or visit
ecommerce.lantheus.com |
Product Information:
A Simple And Efficient Alternative To Needles
For activated DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension only.
INDICATIONS
Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
CONTRAINDICATIONS
Do not administer DEFINITY® to patients with known or suspected right-to-left, bi-directional or transient right-to-left cardiac shunts, by intra-arterial injection, or to patients with known hypersensitivity to perflutren.
IMPORTANT SAFETY INFORMATION
WARNING: Serious Cardiopulmonary Reactions
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [See WARNINGS AND PRECAUTIONS (5.1)]. Most serious reactions occur within 30 minutes of administration.
|
In post marketing use, rare but serious cardiopulmonary or anaphylactoid reactions have been reported during or shortly following perflutren-containing microsphere administration [See ADVERSE REACTIONS (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions [See Postmarketing Experience (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.
Please see full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.
|
|
|
